GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (NAS:ATHE) » Definitions » Shiller PE Ratio

Alterity Therapeutics (Alterity Therapeutics) Shiller PE Ratio : (As of Apr. 25, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Alterity Therapeutics Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alterity Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Alterity Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics Shiller PE Ratio Chart

Alterity Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alterity Therapeutics Quarterly Data
Dec17 Jun18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alterity Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Alterity Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alterity Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's Shiller PE Ratio falls into.



Alterity Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Alterity Therapeutics's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, Alterity Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0/125.6559*125.6559
=0.000

Current CPI (Sep. 2023) = 125.6559.

Alterity Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200803 -0.552 83.864 -0.827
200806 -43.957 85.071 -64.928
200812 -9.274 85.814 -13.580
200906 -8.186 86.278 -11.922
200912 -5.410 87.578 -7.762
201006 -5.944 88.971 -8.395
201012 -9.474 89.993 -13.228
201106 -6.433 92.129 -8.774
201112 -7.287 92.686 -9.879
201206 -3.716 93.244 -5.008
201212 -8.536 94.730 -11.323
201306 -5.326 95.473 -7.010
201312 -10.610 97.330 -13.698
201406 -6.405 98.352 -8.183
201412 -1.288 99.002 -1.635
201506 -4.213 99.838 -5.302
201509 0.000 100.302 0.000
201512 -2.304 100.673 -2.876
201606 -4.086 100.859 -5.091
201612 -2.998 102.159 -3.688
201706 -3.313 102.809 -4.049
201712 -3.119 104.110 -3.765
201806 -3.913 104.945 -4.685
201812 -4.258 105.967 -5.049
201906 -4.208 106.617 -4.959
201909 0.000 107.174 0.000
201912 -2.686 107.917 -3.128
202006 -3.520 106.246 -4.163
202012 -2.937 108.846 -3.391
202103 0.000 109.496 0.000
202106 -1.147 110.332 -1.306
202109 0.000 111.168 0.000
202112 -1.159 112.654 -1.293
202203 0.000 115.069 0.000
202206 -1.096 117.112 -1.176
202209 0.000 119.248 0.000
202212 -1.336 121.477 -1.382
202303 0.000 123.148 0.000
202306 -0.966 124.170 -0.978
202309 0.000 125.656 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alterity Therapeutics  (NAS:ATHE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Alterity Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alterity Therapeutics (Alterity Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.